1 3947 109 LNCRNA UCA1 INDUCES AUTOPHAGIC GENE EXPRESSION VIA EPIGENETIC REGULATION MEDIATED BY ATG16L1 AND MIR-132-3P IN SH-SY5Y CELLS TREATED WITH RETINOIC ACID. OBJECTIVE: EPILEPSY IS A CHRONIC BRAIN DISEASE WITH RECURRENT SEIZURES. AUTOPHAGY PLAYS A CRUCIAL ROLE IN THE PROGRESSION OF EPILEPSY. THIS STUDY AIMED TO EXPLORE THE FUNCTION AND INTRINSIC MECHANISM OF THE LONG NON-CODING RNA (LNCRNA) UCA1/MIR-132-3P/ATG16L1 AXIS IN EPILEPSY VIA REGULATION OF AUTOPHAGY. METHODS: THE EXPRESSION OF LNCRNA UCA1, MIR-132-3P AND ATG16L1 WAS MEASURED IN SERUM FROM EPILEPTIC PATIENTS BY QUANTITATIVE RT-PCR. A SH-SY5Y CELL MODEL WAS FURTHER CONSTRUCTED USING RETINOIC ACID TO INVESTIGATE THE UCA1/ MIR-132-3P/ATG16L1 AXIS BY QUANTITATIVE RT-PCR, WESTERN BLOTTING, FLUORESCENCE IN SITU HYBRIDISATION, RNA IMMUNOPRECIPITATION, CHROMATIN IMMUNOPRECIPITATION, AND A DUAL-LUCIFERASE REPORTER GENE ASSAY. RESULTS: IN THE SERUM OF EPILEPTIC PATIENTS, THE LEVEL OF LNCRNA UCA1 AND ATG16L1 WAS REDUCED AND MIR-132-3P ELEVATED, COMPARED TO CONTROLS. SIMILARLY, IN THE SH-SY5Y CELL MODEL, THE LEVEL OF LNCRNA UCA1 AND ATG16L1 WAS REDUCED AND MIR-132-3P ELEVATED IN RETINOIC ACID-TREATED CELLS; LNCRNA UCA1 WAS MAINLY LOCATED IN THE CYTOPLASM. LNCRNA UCA1 OVEREXPRESSION WAS SHOWN TO PROMOTE AUTOPHAGIC GENE EXPRESSION, WHICH WAS REVERSED BY MIR-132-3P OVEREXPRESSION. MOREOVER, AUTOPHAGIC GENE EXPRESSION INDUCED BY MIR-132-3P KNOCKDOWN WAS REVERSED BY ATG16L1 KNOCKDOWN. BASED ON PRECIPITATION ASSAYS, LNCRNA UCA1 AND MIR-132-3P WERE SHOWN TO FORM A COMPLEX WITH THE TRANSCRIPTION FACTOR, EZH2, AND MIR-132-3P WAS SHOWN TO INTERACT WITH ATG16L1 BASED ON A LUCIFERASE ASSAY. FINALLY, LNCRNA UCA1 WAS SHOWN TO NEGATIVELY REGULATE MIR-132-3P EXPRESSION, AND MIR-132-3P WAS SHOWN TO NEGATIVELY REGULATE ATG16L1. SIGNIFICANCE: IN THIS CELL MODEL, LNCRNA UCA1 PROMOTES AUTOPHAGIC GENE EXPRESSION VIA EPIGENETIC REGULATION MEDIATED BY ATG16L1 AND MIR-132-3P. 2022 2 4573 27 MYOCARDIAL INFARCTION-ASSOCIATED TRANSCRIPT, A LONG NONCODING RNA, IS OVEREXPRESSED DURING DILATED CARDIOMYOPATHY DUE TO CHRONIC CHAGAS DISEASE. LONG NONCODING RNAS (LNCRNAS) MODULATE GENE EXPRESSION AT THE EPIGENETIC, TRANSCRIPTIONAL, AND POSTTRANSCRIPTIONAL LEVELS. DYSREGULATION OF THE LNCRNA KNOWN AS MYOCARDIAL INFARCTION-ASSOCIATED TRANSCRIPT (MIAT) HAS BEEN ASSOCIATED WITH MYOCARDIAL INFARCTION. CHAGAS DISEASE CAUSES A SEVERE INFLAMMATORY DILATED CHRONIC CARDIOMYOPATHY (CCC). WE INVESTIGATED THE ROLE OF MIAT IN CCC. A WHOLE-TRANSCRIPTOME ANALYSIS OF HEART BIOPSY SPECIMENS AND FORMALIN-FIXED, PARAFFIN-EMBEDDED SAMPLES REVEALED THAT MIAT WAS OVEREXPRESSED IN PATIENTS WITH CCC, COMPARED WITH SUBJECTS WITH NONINFLAMMATORY DILATED CARDIOMYOPATHY AND CONTROLS. THESE RESULTS WERE CONFIRMED IN A MOUSE MODEL. RESULTS SUGGEST THAT MIAT IS A SPECIFIC BIOMARKER OF CCC. 2016 3 6235 40 THE M(6)A DEMETHYLASE FTO PROMOTES RENAL EPITHELIAL-MESENCHYMAL TRANSITION BY REDUCING THE M(6)A MODIFICATION OF LNCRNA GAS5. BACKGROUND: RENAL INTERSTITIAL FIBROSIS (RIF) IS THE MAIN PATHOLOGICAL CHANGE OF A VARIETY OF CHRONIC KIDNEY DISEASES (CKD). EPIGENETIC MODIFICATIONS OF FIBROSIS-PRONE GENES REGULATE RIF PROGRESSION. THIS STUDY AIMED TO INVESTIGATE LONG NON-CODING RNA (LNCRNA) N6-METHYLADENOSINE (M(6)A) MODIFICATION AND ITS ROLE IN REGULATING RIF PROGRESSION. METHODS: UNILATERAL URETERAL OCCLUSION (UUO) WAS EMPLOYED TO CONSTRUCT THE RIF IN VIVO MODEL; AND TGF-BETA1-TREATED HK-2 AND HKC-8 CELLS WERE USED FOR IN VITRO EXPERIMENTS. THE MRNA AND PROTEIN EXPRESSIONS WERE ASSESSED USING QRT-PCR AND WESTERN BLOT. THE PROLIFERATION AND MIGRATION WERE EVALUATED BY EDU ASSAY AND TRANSWELL ASSAY, RESPECTIVELY. IN ADDITION, LEVELS OF INFLAMMATORY CYTOKINES WERE DETERMINED BY ELISA ASSAY AND QRT-PCR. MOREOVER, LNCRNA GAS5 M(6)A LEVEL WAS DETECTED USING ME-RIP ASSAY. HE AND MASSON STAINING WERE EMPLOYED TO EVALUATE FIBROTIC LESIONS OF THE KIDNEY. RESULTS: FTO EXPRESSION WAS ELEVATED IN HK-2 AND HKC-8 CELLS AFTER TGF-BETA1 TREATMENT AND MOUSE KIDNEY TISSUE FOLLOWING UUO, AND LNCRNA GAS5 WAS DOWNREGULATED. LNCRNA GAS5 OVEREXPRESSION OR FTO SILENCING SUPPRESSED TGF-BETA1-INDUCED THE INCREASE OF EMT-RELATED PROTEINS (VIMENTIN, SNAIL AND N-CADHERIN) AND INFLAMMATORY CYTOKINES (IL-6, IL-1BETA AND TNF-ALPHA) LEVELS IN HK-2 CELLS. FTO SUPPRESSED LNCRNA GAS5 EXPRESSION BY REDUCING THE M6A MODIFICATION OF LNCRNA GAS5. ADDITIONALLY, FTO KNOCKDOWN COULD SUPPRESS EMT PROCESS AND INFLAMMATION RESPONSE INDUCED BY TGF-BETA1 AND UUO IN VITRO AND IN VIVO. AS EXPECTED, FTO KNOCKDOWN ABROGATED THE PROMOTION EFFECTS OF LNCRNA GAS5 SILENCING ON TGF-BETA1-INDUCED EMT PROCESS AND INFLAMMATION RESPONSE IN HK-2 AND HKC-8 CELLS. CONCLUSION: FTO PROMOTED EMT PROCESS AND INFLAMMATION RESPONSE THROUGH REDUCING THE M(6)A MODIFICATION OF LNCRNA GAS5. 2022 4 1727 28 DYSREGULATION OF LONG NON-CODING RNAS IN MOUSE MODELS OF LOCALIZATION-RELATED EPILEPSY. GENOME-WIDE PROFILING HAS REVEALED THAT EUKARYOTIC GENOMES ARE TRANSCRIBED INTO NUMEROUS NON-CODING RNAS. IN PARTICULAR, LONG NON-CODING RNAS (LNCRNAS) HAVE BEEN IMPLICATED IN VARIOUS HUMAN DISEASES DUE TO THEIR BIOCHEMICAL AND FUNCTIONAL DIVERSITY. EPILEPTIC DISORDERS HAVE BEEN CHARACTERIZED BY DYSREGULATION OF EPIGENETIC REGULATORY MECHANISMS, AND RECENT STUDIES HAVE IDENTIFIED SEVERAL LNCRNAS INVOLVED IN NEURAL DEVELOPMENT AND NETWORK FUNCTION. HOWEVER, COMPREHENSIVE PROFILING OF LNCRNAS IMPLICATED IN CHRONIC EPILEPSY HAS BEEN LACKING. IN THIS STUDY, MICROARRAY ANALYSIS WAS PERFORMED TO OBTAIN THE EXPRESSION PROFILE OF LNCRNAS DYSREGULATED IN PILOCARPINE AND KAINATE MODELS, TWO MODELS OF TEMPORAL LOBE EPILEPSY COMMONLY USED FOR STUDYING EPILEPTIC MECHANISMS. TOTAL OF 4622 LNCRNAS WERE ANALYZED: 384 LNCRNAS WERE SIGNIFICANTLY DYSREGULATED IN PILOCARPINE MODEL, AND 279 LNCRNAS WERE SIGNIFICANTLY DYSREGULATED IN KAINATE MODEL COMPARED WITH CONTROL MICE (>/=3.0-FOLD, P < 0.05). AMONG THESE, 54 AND 14 LNCRNAS, RESPECTIVELY, HAD ADJACENT PROTEIN-CODING GENES WHOSE EXPRESSIONS WERE ALSO SIGNIFICANTLY DYSREGULATED (>/=2.0-FOLD, P < 0.05). MAJORITY OF THESE PAIRS OF LNCRNAS AND ADJACENT GENES SHARED THE SAME DIRECTION OF DYSREGULATION. FOR THE SELECTED ADJACENT GENE-LNCRNA PAIRS, SIGNIFICANT GENE ONTOLOGY TERMS WERE EMBRYONIC APPENDAGE MORPHOGENESIS AND NEURON DIFFERENTIATION. THIS WAS THE FIRST STUDY TO COMPREHENSIVELY IDENTIFY DYSREGULATED LNCRNAS IN TWO DIFFERENT MODELS OF CHRONIC EPILEPSY AND WILL LIKELY PROVIDE A NOVEL INSIGHT INTO DEVELOPING LNCRNA THERAPEUTICS. 2015 5 1718 28 DYSREGULATED LONG NON-CODING RNAS IN THE TEMPORAL LOBE EPILEPSY MOUSE MODEL. PURPOSE: TO PERFORM COMPREHENSIVE PROFILING OF LONG NON-CODING RNAS (LNCRNAS) IN TEMPORAL LOBE EPILEPSY. METHODS: WE PERFORMED EXTENSIVE PROFILING OF LNCRNAS AND MRNAS IN THE MOUSE PILOCARPINE MODEL IN SPECIFIC BRAIN REGIONS, THE HIPPOCAMPUS AND CORTEX, AND COMPARED THE RESULTS TO THOSE OF THE CONTROL MOUSE. DIFFERENTIALLY EXPRESSED LNCRNAS AND MRNAS WERE IDENTIFIED WITH A MICROARRAY ANALYSIS (ARRAYSTAR MOUSE LNCRNA EXPRESSION MICROARRAY V3.0). THEN, GENE ONTOLOGY (GO) AND PATHWAY ANALYSIS WERE PERFORMED TO INVESTIGATE THE POTENTIAL ROLES OF THE DIFFERENTIALLY EXPRESSED MRNAS IN THE PILOCARPINE MODEL. PROTEIN-PROTEIN INTERACTIONS TRANSCRIBED BY DYSREGULATED MRNAS WITH/WITHOUT CO-DYSREGULATED LNCRNAS WERE ANALYZED USING STRING V10 (HTTP://STRING-DB.ORG/). RESULTS: A TOTAL OF 22 AND 83 LNCRNAS WERE UP- AND DOWN-REGULATED (>/=2.0-FOLD, ALL P < .05), RESPECTIVELY, IN THE HIPPOCAMPUS OF THE EPILEPSY MODEL, WHILE 46 AND 659 LNCRNAS WERE UP- AND DOWN-REGULATED, RESPECTIVELY, IN THE CORTEX OF THE EPILEPSY MODEL. GO AND PATHWAY ANALYSIS REVEALED THAT THE DYSREGULATED MRNAS WERE CLOSELY ASSOCIATED WITH A PROCESS ALREADY KNOWN TO BE INVOLVED IN EPILEPTOGENESIS: ACUTE INFLAMMATION, CALCIUM ION REGULATION, EXTRACELLULAR MATRIX REMODELING, AND NEURONAL DIFFERENTIATION. AMONG THE LNCRNAS, WE IDENTIFIED 10 LNCRNAS COMMONLY DYSREGULATED WITH CORRESPONDING MRNAS IN THE CORTEX. THE STRING ANALYSIS SHOWED THAT THE DYSREGULATED MRNAS WERE INTERCONNECTED AROUND TWO CENTERS: THE MTOR PATHWAY-RELATED GENES AND REST PATHWAY-RELATED GENES. CONCLUSION: LNCRNAS WERE DYSREGULATED IN THE PILOCARPINE MOUSE MODEL ACCORDING TO THE BRAIN REGIONS OF THE HIPPOCAMPUS AND CORTEX. THE DYSREGULATED LNCRNAS WITH CO-DYSREGULATED MRNAS MIGHT BE POSSIBLE THERAPEUTIC TARGETS FOR THE EPIGENETIC REGULATION OF CHRONIC EPILEPSY. 2018 6 1484 29 DLEU2: A MEANINGFUL LONG NONCODING RNA IN ONCOGENESIS. BACKGROUND: LONG NON-CODING RNA (LNCRNA) WITH LITTLE OR NO CODING ABILITY HAS SHOWN A VARIETY OF BIOLOGICAL FUNCTIONS IN CANCER, INCLUDING EPIGENETIC REGULATION, DNA DAMAGE, REGULATION OF MICRORNAS, AND PARTICIPATION IN SIGNAL TRANSDUCTION PATHWAYS. LNCRNA CAN BE USED AS AN ONCOGENE AND TUMOR SUPPRESSOR GENE THROUGH TRANSCRIPTIONAL REGULATION IN CANCER. FOR EXAMPLE, THE OVER-EXPRESSED LNCRNA DLEU2 PROMOTES THE OCCURRENCE OF LARYNGEAL CANCER, LUNG CANCER, HEPATOCELLULAR CARCINOMA, ETC., AND INHIBITS THE PROGRESSION OF CHRONIC LYMPHOCYTIC LEUKEMIA. DELETED IN LYMPHOCYTIC LEUKEMIA 2 (DLEU2), AS ONE OF THE LONG NON-CODING RNAS, WAS FIRST FOUND IN CHRONIC LYMPHOBLASTIC LEUKEMIA AND DRAWN INTO THE PROGRESS OF INNUMERABLE CANCERS. THE MOLECULAR MECHANISM OF DLEU2 IN MULTIPLE TUMORS WILL BE REVEALED. METHODS: IN THIS REVIEW, CURRENT STUDIES ON THE BIOLOGICAL FUNCTIONS AND MECHANISMS OF DLEU2 IN TUMORS ARE SUMMARIZED AND ANALYZED; RELATED RESEARCHES ARE SYSTEMATICALLY RETRIEVED AND COLLECTED THROUGH PUBMED. RESULTS: DLEU2, A NOVEL CANCER-RELATED LNCRNA, HAS BEEN DEMONSTRATED TO BE ABNORMALLY EXPRESSED IN VARIOUS MALIGNANT TUMORS, INCLUDING LEUKEMIA, ESOPHAGEAL CANCER, LUNG CANCER, GLIOMA, HEPATOCELLULAR CARCINOMA, MALIGNANT PLEURAL MESOTHELIOMA, BLADDER CANCER, PANCREATIC CANCER, PHARYNX AND THROAT CANCER, RENAL CLEAR CELL CARCINOMA, BREAST CANCER, OSTEOSARCOMA. BESIDES, LNCRNA DLEU2 HAS BEEN SHOWN TO BE INVOLVED IN THE PROCESS OF PROLIFERATION, MIGRATION, INVASION AND INHIBITION OF APOPTOSIS OF CANCER CELLS. CONCLUSION: DUE TO THE BIOLOGICAL FUNCTIONS AND MECHANISMS INVOLVED IN DLEU2, IT MAY REPRESENT AN AVAILABLE BIOMARKER OR POTENTIAL THERAPEUTIC TARGET IN A VARIETY OF MALIGNANT TUMORS. 2021 7 2768 33 EXPRESSIONS OF SERUM LNCRNAS IN DIABETIC RETINOPATHY - A POTENTIAL DIAGNOSTIC TOOL. WITH INCREASING INCIDENCE OF DIABETES WORLDWIDE, THERE IS AN EVER-EXPANDING NUMBER OF PATIENTS WITH CHRONIC DIABETIC COMPLICATIONS SUCH AS DIABETIC RETINOPATHY (DR), ONE OF THE LEADING CAUSES OF BLINDNESS IN THE WORKING AGE POPULATION. EARLY SCREENING FOR THE ONSET AND SEVERITY OF DR IS ESSENTIAL FOR TIMELY INTERVENTION. WITH RECENT ADVANCEMENTS IN GENOMIC TECHNOLOGIES, EPIGENETIC ALTERATIONS IN DR ARE BEGINNING TO UNRAVEL. LONG NON-CODING RNAS (LNCRNAS), WHICH ARE KEY EPIGENETIC MEDIATORS, HAVE DEMONSTRATED IMPLICATIONS IN SEVERAL (DR) RELATED PROCESSES. BASED ON THE PREVIOUS RESEARCH, WE HAVE DEVELOPED A SERUM-BASED, MULTI-PANEL PCR TEST USING 9 LNCRNAS (ANRIL, MALAT1, WISPER, ZFAS1, H19, HOTAIR, HULC, MEG3, AND MIAT) TO IDENTIFY AND VALIDATE WHETHER THIS PANEL COULD BE USED AS A DIAGNOSTIC AND PROGNOSTIC TOOL FOR DR. WE INITIALLY USED A CELL CULTURE MODEL (HUMAN RETINAL ENDOTHELIAL CELLS) AND CONFIRMED THAT 25 MM GLUCOSE INDUCES UPREGULATIONS OF ANRIL, HOTAIR, HULC, MALAT1, AND ZFAS1, AND DOWNREGULATION OF H19 COMPARED TO 5 MM GLUCOSE CONTROLS. THEN AS AN INITIAL PROOF-OF-CONCEPT, WE TESTED VITREOUS HUMOR AND SERUM SAMPLES FROM A SMALL COHORT OF NON-DIABETIC (N=10) AND DIABETIC PATIENTS WITH PROLIFERATIVE RETINOPATHY (PDR, N=11) AND MEASURED THE LEVELS OF THE 9 LNCRNAS. DIFFERENTIAL EXPRESSIONS OF LNCRNAS WERE FOUND IN THE VITREOUS AND SERUM OF PATIENTS AND SHOWED SIGNIFICANT CORRELATIONS. WE EXPANDED OUR APPROACH AND ASSESSED THE SAME LNCRNAS USING SAMPLES FROM A LARGER COHORT OF DIABETIC (N= 59; M/F:44/15) AND NON-DIABETIC PATIENTS (N= 11; M/F:4/7). SIGNIFICANT INCREASED LNCRNA EXPRESSIONS OF ANRIL, H19, HOTAIR, HULC, MIAT, WISPER AND ZFAS1 WERE OBSERVED IN THE SERUM OF DIABETIC PATIENTS (WITH VARYING STAGES OF DR) COMPARED TO NON-DIABETICS. NO SIGNIFICANT CORRELATIONS WERE DEMONSTRATED BETWEEN LNCRNA EXPRESSIONS AND CREATININE OR GLYCATED HEMOGLOBIN (HBA1C) LEVELS. USING ROC AND FURTHER ANALYSES, WE IDENTIFIED DISTINCT LNCRNA PHENOTYPE COMBINATIONS, WHICH MAY BE USED TO IDENTIFY PATIENTS WITH DR. DATA FROM THIS STUDY INDICATE THAT A PANEL OF SERUM LNCRNAS MAY BE USED FOR A POTENTIAL SCREENING TEST FOR DR. FURTHER LARGE-SCALE STUDIES ARE NEEDED TO VALIDATE THIS NOTION. 2022 8 412 32 ANALYSIS OF LONG NON-CODING RNA (LNCRNA) EXPRESSION IN HEPATITIS B PATIENTS. LONG NON-CODING RNAS (LNCRNAS) HAVE BEEN IMPLICATED IN NUMEROUS BIOLOGICAL PROCESSES, INCLUDING EPIGENETIC REGULATION, CELL-CYCLE CONTROL, AND TRANSCRIPTIONAL/TRANSLATIONAL REGULATION OF GENE EXPRESSION. DIFFERENTIAL EXPRESSION OF LNCRNAS AND DISRUPTION OF THE REGULATORY PROCESSES ARE RECOGNIZED AS CRITICAL STEPS IN CANCER DEVELOPMENT. THE ROLE OF LNCRNAS IN HEPATITIS B VIRUS (HBV) INFECTION IS NOT WELL UNDERSTOOD. HERE WE ANALYZED THE EXPRESSION OF 135 LNCRNAS IN PLASMA SAMPLES OF 82 HBV PATIENTS (CLASSIFIED AS CHRONIC PATIENTS, INACTIVE CARRIERS, OR RESOLVED PATIENTS) AT DIAGNOSIS AND AT 12 MONTHS OF TREATMENT IN RELATION TO CONTROL GROUP (81 HEALTHY VOLUNTEERS). WE ALSO INVESTIGATED THE EFFECT OF SMALL INTERFERING RNA (SIRNA)-MEDIATED SILENCING OF LINCRNA-SFMBT2 ON HBV-POSITIVE HUMAN LIVER CANCER CELL LINE. LNCRNA EXPRESSION WAS ANALYZED BY QUANTITATIVE REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION (QRT-PCR). CHEMICALLY SYNTHESIZED SIRNAS WERE TRANSFECTED INTO THE CELL LINES USING LIPOFECTAMINE 2000 REAGENT (THERMO FISHER SCIENTIFIC). HBV DNA AND HBSAG AND HBEAG WERE DETECTED IN TRANSFECTED CULTURES BY REAL-TIME PCR AND ELISA, RESPECTIVELY, USING COMMERCIAL KITS. WE OBSERVED CHANGES IN LNCRNA EXPRESSION IN ALL THREE HBV GROUPS, COMPARED TO CONTROL GROUP. MOST NOTABLY, THE EXPRESSION OF ANTI-NOS2A, LINCRNA-SFMBT2, AND ZFHX2AS WAS SIGNIFICANTLY INCREASED AND EXPRESSION OF Y5 LNCRNA WAS DECREASED IN CHRONIC HBV PATIENTS. A DECREASED Y5 EXPRESSION AND INCREASED LINCRNA-SFMBT2 EXPRESSION WERE OBSERVED IN INACTIVE HBSAG CARRIERS. THE EXPRESSION OF HOTTIP, MEG9, AND PCAT-32 WAS INCREASED IN RESOLVED HBV PATIENTS, AND NO SIGNIFICANT CHANGE IN THE EXPRESSION OF Y5 WAS OBSERVED, COMPARED TO CONTROL GROUP. SIRNA-MEDIATED INHIBITION OF LINCRNA-SFMBT2 DECREASED THE LEVEL OF HBV DNA IN HUMAN LIVER CANCER CELLS. FURTHER RESEARCH IS NEEDED TO CONFIRM THE PROGNOSTIC AS WELL AS THERAPEUTIC ROLE OF THESE LNCRNAS IN HBV PATIENTS. 2018 9 263 19 ADVANCES WITH LONG NON-CODING RNAS IN DIABETIC PERIPHERAL NEUROPATHY. LONG NON-CODING RNAS (?LNCRNAS) ?ARE A GROUP OF NON-CODING RNAS LONGER THAN 200 NUCLEOTIDES, WHICH ARE DEFINED AS TRANSCRIPTS. THE LNCRNAS ARE INVOLVED IN REGULATING GENE EXPRESSION AT EPIGENETIC, TRANSCRIPTIONAL, AND POST-TRANSCRIPTIONAL LEVELS. RECENT STUDIES HAVE FOUND THAT LNCRNA IS CLOSELY RELATED TO MANY DISEASES LIKE NEUROLOGICAL DISEASES, ENDOCRINE AND METABOLIC DISORDERS. DIABETIC PERIPHERAL NEUROPATHY (DPN) IS ONE OF THE MOST COMMON CHRONIC COMPLICATIONS OF DIABETES MELLITUS. IN THIS REVIEW, WE HIGHLIGHT THE LATEST RESEARCH RELATED TO LNCRNAS IN DPN. 2020 10 6231 33 THE LONG NONCODING RNA MEG3 AND ITS TARGET MIR-147 REGULATE JAK/STAT PATHWAY IN ADVANCED CHRONIC MYELOID LEUKEMIA. BACKGROUND: LONG NON-CODING (LNC) RNAS PLAYS AN IMPORTANT ROLE IN CHRONIC MYELOID LEUKEMIA (CML). IN THIS STUDY, WE AIMED TO UNCOVER THE MECHANISM OF THE LNCRNA MATERNALLY EXPRESSED 3 (MEG3) AND ITS TARGET MICRORNA-147 (MIR-147) IN CML. METHODS: SIXTY CML PATIENTS AND 10 HEALTHY DONORS WERE INCLUDED IN THE STUDY. THE METHYLATION OF MEG3 AND MIR-147 PROMOTER WAS DETERMINED BY METHYLATION-SPECIFIC PCR. THE RELATIONSHIP OF MEG3 AND MIR-147 WAS EXPLORED BY LUCIFERASE ASSAY. THE INTERACTIONS OF PROTEINS WERE STUDIED BY RNA PULL-DOWN ASSAY, RNA IMMUNOPRECIPITATION AND CO-IMMUNOPRECIPITATION. FINDINGS: PATIENTS IN ACCELERATED PHASE CML (CML-AP) AND BLAST PHASE CML (CML-BP) SHOWED LOWER EXPRESSIONS OF MEG3 AND MIR-147 AND HIGHER EXPRESSIONS OF DNMT1, DNMT3B, MBD2, MECP2 AND HDAC1 COMPARED TO THE CONTROLS. THESE PATIENTS ALSO SHOWED A HIGHER DEGREE OF METHYLATION OF MEG3 AND MIR-147 WHILE THERE WAS A REDUCTION AFTER CHIDAMIDE TREATMENT. FURTHERMORE, THE OVEREXPRESSION OF MEG3 AND MIR-147 INHIBITED CELL PROLIFERATION BOTH IN VIVO AND IN VITRO, PROMOTED APOPTOSIS AND DECREASED THE EXPRESSIONS OF DNMT1, DNMT3A, DNMT3B, MBD2, HDAC1 AND MECP2. WE ALSO FOUND MEG3 INTERACTED WITH DNMT1, JAK2, STAT3, HDAC1, AND TYK2, AND JAK2 WAS BOUND TO STAT3, STAT5 AND MYC. MORE INTERESTINGLY, JAK2 WAS BOUND TO TYK2 BY THE BRIDGE OF MEG3. INTERPRETATION: LNCRNA MEG3 AND ITS TARGET MIR-147 MAY SERVE AS A NOVEL THERAPEUTIC TARGET FOR CML BLAST CRISIS, AND CHIDAMIDE MIGHT HAVE A POTENTIAL CLINICAL APPLICATION IN TREATING CML BLAST CRISIS. 2018 11 3946 33 LNCRNA MALAT1 BINDS CHROMATIN REMODELING SUBUNIT BRG1 TO EPIGENETICALLY PROMOTE INFLAMMATION-RELATED HEPATOCELLULAR CARCINOMA PROGRESSION. HEPATOCELLULAR CARCINOMA (HCC) IS ONE TYPE OF CANCERS WHOSE CARCINOGENESIS AND PROGRESSION ARE CLOSELY RELATED TO CHRONIC INFLAMMATION. IDENTIFYING THE MOLECULAR MECHANISMS FOR INFLAMMATION-RELATED HCC PROGRESSION WILL CONTRIBUTE TO IMPROVE THE EFFICACY OF CURRENT THERAPEUTICS FOR HCC PATIENTS. MANY KINDS OF EPIGENETIC FACTORS, INCLUDING LONG NON-CODING RNAS (LNCRNAS), HAVE BEEN DISCOVERED TO BE IMPORTANT IN HCC GROWTH AND METASTASIS. HOWEVER, HOW THE LNCRNAS PROMOTE HCC PROGRESSION AND WHAT'S THE APPLICATION OF LNCRNA SILENCING IN VIVO IN SUPPRESSING HCC REMAIN TO BE FURTHER INVESTIGATED. HERE, WE FOUND THAT LNCRNA METASTASIS ASSOCIATED LUNG ADENOCARCINOMA TRANSCRIPT1 (MALAT1) WAS UPREGULATED IN HCC TUMOR TISSUES, AND KNOCKDOWN OF MALAT1 SUPPRESSED PROLIFERATION, CELL CYCLE AND INVASION OF HCC CELLS IN RESPONSE TO LIPOPOLYSACCHARIDE (LPS) STIMULATION. KNOCKDOWN OF MALAT1 SIGNIFICANTLY INHIBITED LPS-INDUCED PRO-INFLAMMATORY MEDIATORS IL-6 AND CXCL8 EXPRESSION IN HCC CELLS, WHICH COULD BE RESTORED BY OVEREXPRESSING MALAT1. MECHANISTICALLY, MALAT1 RECRUITED BRAHMA-RELATED GENE 1 (BRG1), A CATALYTIC SUBUNIT OF CHROMATIN REMODELING COMPLEX SWITCHING/SUCROSE NON-FERMENTABLE (SWI/SNF), TO THE PROMOTER REGION OF IL-6 AND CXCL8, AND THUS FACILITATED NF-KAPPAB TO INDUCE THE EXPRESSION OF THESE INFLAMMATORY FACTORS. IMPORTANTLY, IN VIVO SILENCING OF MALAT1 IN HCC TISSUES INHIBITED GROWTH OF HCC XENOGRAFTS, AND ALSO SUPPRESSED THE EXPRESSION OF PRO-INFLAMMATORY FACTORS IN HCC TISSUES ACCORDINGLY. OUR RESULTS DEMONSTRATE THAT MALAT1 PROMOTES HCC PROGRESSION BY BINDING BRG1 TO EPIGENETICALLY ENHANCE INFLAMMATORY RESPONSE IN HCC TISSUES, AND SILENCING OF MALAT1 MAY BE A POTENTIAL APPROACH TO THE TREATMENT OF HCC. 2019 12 1866 23 EMERGING CROSSTALK BETWEEN LONG NON-CODING RNAS AND NRF2 SIGNALING. DIVERSE STIMULI TRIGGER NRF2 SIGNALING, WHICH IN TURN TRANSCRIPTIONALLY REGULATES AN ARRAY OF DOWNSTREAM TARGETS, PROVIDING FOR MULTIPLE LAYERS OF CONTROL. WHILE NRF2 ACTIVITY LARGELY IS GOVERNED BY POSTTRANSLATIONAL MODIFICATION OF CRITICAL THIOL RESIDUES IN THE PROTEIN PARTNER AND REDOX SENSOR KEAP1, FINE-TUNING IS PROVIDED BY ADDITIONAL MECHANISMS - INCLUDING EPIGENETIC REGULATION. HEREIN, WE REVIEW THE EMERGING SIGNIFICANCE OF LONG NON-CODING RNAS (LNCRNA) AS DOWNSTREAM TARGETS AND UPSTREAM REGULATORS OF THE NRF2 SIGNALING PATHWAY. AMONG THE ~16000 LNCRNAS IN GENCODE, SOME HAVE BEEN VALIDATED AS TRANSCRIPTIONALLY REGULATED BY NRF2 (E.G., LUCAT1, NMRAL2P, ODRUL, ROR AND TUG1), AND OTHERS HAVE BEEN IDENTIFIED AS UPSTREAM REGULATORS OF NRF2 EXPRESSION (E.G., HOTAIR, MALAT1, MEG1, NRAL AND UCA1). BIOINFORMATIC ANALYSES OF ANNOTATED HUMAN LNCRNAS IDENTIFIED PUTATIVE NRF2 BINDING SITES IN THE PROMOTER REGIONS OF 13,285 LNCRNAS. FURTHER INVESTIGATION IS WARRANTED TO VALIDATE THE MANY NOVEL LNCRNAS AS BONA FIDE NRF2-REGULATED TARGETS, AND THEIR ROLES IN NRF2 SIGNALING. NRF2 IS CONSIDERED A PROMISING THERAPEUTIC CANDIDATE FOR CANCER AND OTHER CHRONIC DISEASES; THUS, TARGETING THE ASSOCIATED LNCRNAS MIGHT PROVIDE FOR A MORE REFINED FINE-TUNING OF THE SYSTEM, DEPENDING ON CELLULAR AND PATHOPHYSIOLOGICAL CONTEXT. 2020 13 5120 27 POSSIBLE EPIGENETIC REGULATORY EFFECT OF DYSREGULATED CIRCULAR RNAS IN EPILEPSY. CIRCULAR RNAS (CIRCRNAS) INVOLVE IN THE EPIGENETIC REGULATION AND ITS MAJOR MECHANISM IS THE SEQUESTRATION OF THE TARGET MICRO RNAS (MIRNAS). WE HYPOTHESIZED THAT CIRCRNAS MIGHT BE RELATED WITH THE PATHOPHYSIOLOGY OF CHRONIC EPILEPSY AND EVALUATED THE ALTERED CIRCRNA EXPRESSIONS AND THEIR POSSIBLE REGULATORY EFFECTS ON THEIR TARGET MIRNAS AND MRNAS IN A MOUSE EPILEPSY MODEL. THE CIRCRNA EXPRESSION PROFILE IN THE HIPPOCAMPUS OF THE PILOCARPINE MICE WAS ANALYZED AND COMPARED WITH CONTROL. THE CORRELATION BETWEEN THE EXPRESSION OF MIRNA BINDING SITES (MIRNA RESPONSE ELEMENTS, MRE) IN THE DYSREGULATED CIRCRNAS AND THE EXPRESSION OF THEIR TARGET MIRNAS WAS EVALUATED. AS MIRNAS ALSO INHIBIT THEIR TARGET MRNAS, CIRCRNA-MIRNA-MRNA REGULATORY NETWORK, COMPRISED OF DYSREGULATED RNAS THAT TARGETS ONE ANOTHER WERE SEARCHED. FOR THE IDENTIFIED NETWORKS, BIOINFORMATICS ANALYSES WERE PERFORMED. AS THE RESULT, FORTY-THREE CIRCRNAS WERE DYSREGULATED IN THE HIPPOCAMPUS (UP-REGULATED, 26; DOWN-REGULATED, 17). THE CHANGE IN THE EXPRESSION OF MRE IN THOSE CIRCRNAS NEGATIVELY CORRELATED WITH THE CHANGE IN THE RELEVANT TARGET MIRNA EXPRESSION (R = -0.461, P<0.001), SUPPORTING THAT CIRCRNAS INHIBIT THEIR TARGET MIRNA. 333 DYSREGULATED CIRCRNA-MIRNA-MRNA NETWORKS WERE IDENTIFIED. GENE ONTOLOGY AND PATHWAY ANALYSES DEMONSTRATED THAT THE UP-REGULATED MRNAS IN THOSE NETWORKS WERE CLOSELY RELATED TO THE MAJOR PROCESSES IN EPILEPSY. AMONG THEM, STRING ANALYSIS IDENTIFIED 37 KEY MRNAS WITH ABUNDANT (>/=4) INTERACTIONS WITH OTHER DYSREGULATED TARGET MRNAS. THE DYSREGULATION OF THE CIRCRNAS WHICH HAD MULTIPLE INTERACTIONS WITH KEY MRNAS WERE VALIDATED BY PCR. WE CONCLUDED THAT DYSREGULATED CIRCRNAS MIGHT HAVE A PATHOPHYSIOLOGIC ROLE IN CHRONIC EPILEPSY BY REGULATING MULTIPLE DISEASE RELEVANT MRNAS VIA CIRCRNA-MIRNA-MRNA INTERACTIONS. 2018 14 1022 41 CIRCULAR RNA HSA_CIRC_0098181 INHIBITS METASTASIS IN HEPATOCELLULAR CARCINOMA BY ACTIVATING THE HIPPO SIGNALING PATHWAY VIA INTERACTION WITH EEF2. INTRODUCTION AND OBJECTIVES: THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA (HCC) IS A MULTI-STEP PROCESS THAT ACCUMULATES GENETIC AND EPIGENETIC ALTERATIONS, INCLUDING CHANGES IN CIRCULAR RNA (CIRCRNA). THIS STUDY AIMED TO UNDERSTAND THE ALTERATIONS IN CIRCRNA EXPRESSION IN HCC DEVELOPMENT AND METASTASIS AND TO EXPLORE THE BIOLOGICAL FUNCTIONS OF CIRCRNA. MATERIALS AND METHODS: TEN PAIRS OF ADJACENT CHRONIC HEPATITIS TISSUES AND HCC TISSUES FROM PATIENTS WITHOUT VENOUS METASTASES, AND TEN HCC TISSUES FROM PATIENTS WITH VENOUS METASTASES WERE ANALYZED USING HUMAN CIRCRNA MICROARRAYS. DIFFERENTIALLY EXPRESSED CIRCRNAS WERE THEN VALIDATED BY QUANTITATIVE REAL-TIME PCR. IN VITRO AND IN VIVO ASSAYS WERE PERFORMED TO ASSESS THE ROLES OF THE CIRCRNA IN HCC PROGRESSION. RNA PULL-DOWN ASSAY, MASS SPECTROMETRY ANALYSIS, AND RNA-BINDING PROTEIN IMMUNOPRECIPITATION WERE CONDUCTED TO EXPLORE THE PROTEIN PARTNERS OF THE CIRCRNA. RESULTS: CIRCRNA MICROARRAYS REVEALED THAT THE EXPRESSION PATTERNS OF CIRCRNAS ACROSS THE THREE GROUPS WERE SIGNIFICANTLY DIFFERENT. AMONG THESE, HSA_CIRC_0098181 WAS VALIDATED TO BE LOWLY EXPRESSED AND ASSOCIATED WITH POOR PROGNOSIS IN HCC PATIENTS. ECTOPIC EXPRESSION OF HSA_CIRC_0098181 DELAYED HCC METASTASIS IN VITRO AND IN VIVO. MECHANISTICALLY, HSA_CIRC_0098181 SEQUESTERED EUKARYOTIC TRANSLATION ELONGATION FACTOR 2 (EEF2) AND DISSOCIATED EEF2 FROM FILAMENTOUS ACTIN (F-ACTIN) TO PREVENT F-ACTIN FORMATION, WHICH BLOCKED ACTIVATION OF THE HIPPO SIGNALING PATHWAY. IN ADDITION, THE RNA BINDING PROTEIN QUAKING-5 BOUND DIRECTLY TO HSA_CIRC_0098181 AND INDUCED ITS BIOGENESIS. CONCLUSIONS: OUR STUDY REVEALS CHANGES IN CIRCRNA EXPRESSION FROM CHRONIC HEPATITIS, PRIMARY HCC, TO METASTATIC HCC. FURTHER, THE QKI5-HSA_CIRC_0098181-EEF2-HIPPO SIGNALING PATHWAY EXERTS A REGULATORY ROLE IN HCC. 2023 15 3000 26 GENETIC VARIATIONS IN UCA1, A LNCRNA FUNCTIONING AS A MIRNA SPONGE, DETERMINE ENDOMETRIOSIS DEVELOPMENT AND THE POTENTIAL ASSOCIATED INFERTILITY VIA REGULATING LIPOGENESIS. ENDOMETRIOSIS IS A HORMONE-ASSOCIATED DISEASE WHICH HAS BEEN CONSIDERED AS THE PRECURSOR FOR CERTAIN TYPES OF OVARIAN CANCER. IN RECENT YEARS, EMERGING EVIDENCE DEMONSTRATED POTENT ROLES OF LNCRNA IN REGULATING CANCER DEVELOPMENT. SINCE ENDOMETRIOSIS SHARES SEVERAL FEATURES WITH CANCER, WE INVESTIGATED THE POSSIBLE INVOLVEMENT OF CANCER-RELATED LNCRNAS IN ENDOMETRIOSIS, INCLUDING UCA1, GAS5 AND PTENP1. BY USING MASSARRAY SYSTEM, WE INVESTIGATED CERTAIN GENETIC VARIATIONS IN CANCER-RELATED LNCRNAS THAT CAN CHANGE THE THERMO-STABILITY, LEADING TO UP-REGULATION OR DOWN-REGULATION OF THOSE LNCRNAS. OUR DATA INDICATED THREE RISK GENETIC HAPLOTYPES IN UCA1 WHICH CAN STABILIZE THE RNA STRUCTURE AND INCREASE THE SUSCEPTIBILITY OF ENDOMETRIOSIS. OF NOTE, SUCH ALTERATIONS WERE FOUND TO BE ASSOCIATED WITH LONG-TERM PAIN AND INFERTILITY IN PATIENTS. IT HAS BEEN KNOWN THAT UCA1 CAN FUNCTION AS A CERNA TO SPONGE AND INHIBIT MIRNAS, RESULTING IN LOSS-OF-CONTROL ON DOWNSTREAM TARGET GENES. GENE NETWORK ANALYSES REVEALED FATTY ACID METABOLISM AND MITOCHONDRIA BETA-OXIDATION AS THE MAJOR PATHWAYS ASSOCIATED WITH ALTERED UCA1 EXPRESSION IN ENDOMETRIOSIS PATIENTS. OUR STUDY THUS PROVIDES EVIDENCE TO HIGHLIGHT FUNCTIONAL/EPIGENETIC ROLES OF UCA1 IN ENDOMETRIOSIS DEVELOPMENT VIA REGULATING FATTY ACID METABOLISM IN WOMEN. 2022 16 2481 36 EPIGENETIC UPREGULATION OF LNCRNAS AT 13Q14.3 IN LEUKEMIA IS LINKED TO THE IN CIS DOWNREGULATION OF A GENE CLUSTER THAT TARGETS NF-KB. NON-CODING RNAS ARE MUCH MORE COMMON THAN PREVIOUSLY THOUGHT. HOWEVER, FOR THE VAST MAJORITY OF NON-CODING RNAS, THE CELLULAR FUNCTION REMAINS ENIGMATIC. THE TWO LONG NON-CODING RNA (LNCRNA) GENES DLEU1 AND DLEU2 MAP TO A CRITICAL REGION AT CHROMOSOMAL BAND 13Q14.3 THAT IS RECURRENTLY DELETED IN SOLID TUMORS AND HEMATOPOIETIC MALIGNANCIES LIKE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). WHILE NO POINT MUTATIONS HAVE BEEN FOUND IN THE PROTEIN CODING CANDIDATE GENES AT 13Q14.3, THEY ARE DEREGULATED IN MALIGNANT CELLS, SUGGESTING AN EPIGENETIC TUMOR SUPPRESSOR MECHANISM. WE THEREFORE CHARACTERIZED THE EPIGENETIC MAKEUP OF 13Q14.3 IN CLL CELLS AND FOUND HISTONE MODIFICATIONS BY CHROMATIN-IMMUNOPRECIPITATION (CHIP) THAT ARE ASSOCIATED WITH ACTIVATED TRANSCRIPTION AND SIGNIFICANT DNA-DEMETHYLATION AT THE TRANSCRIPTIONAL START SITES OF DLEU1 AND DLEU2 USING 5 DIFFERENT SEMI-QUANTITATIVE AND QUANTITATIVE METHODS (APRIMES, BIOCOBRA, MCIP, MASSARRAY, AND BISULFITE SEQUENCING). THESE EPIGENETIC ABERRATIONS WERE CORRELATED WITH TRANSCRIPTIONAL DEREGULATION OF THE NEIGHBORING CANDIDATE TUMOR SUPPRESSOR GENES, SUGGESTING A COREGULATION IN CIS OF THIS GENE CLUSTER. WE FOUND THAT THE 13Q14.3 GENES IN ADDITION TO THEIR PREVIOUSLY KNOWN FUNCTIONS REGULATE NF-KB ACTIVITY, WHICH WE COULD SHOW AFTER OVEREXPRESSION, SIRNA-MEDIATED KNOCKDOWN, AND DOMINANT-NEGATIVE MUTANT GENES BY USING WESTERN BLOTS WITH PREVIOUSLY UNDESCRIBED ANTIBODIES, BY A CUSTOMIZED ELISA AS WELL AS BY REPORTER ASSAYS. IN ADDITION, WE PERFORMED AN UNBIASED SCREEN OF 810 HUMAN MIRNAS AND IDENTIFIED THE MIR-15/16 FAMILY OF GENES AT 13Q14.3 AS THE STRONGEST INDUCERS OF NF-KB ACTIVITY. IN SUMMARY, THE TUMOR SUPPRESSOR MECHANISM AT 13Q14.3 IS A CLUSTER OF GENES CONTROLLED BY TWO LNCRNA GENES THAT ARE REGULATED BY DNA-METHYLATION AND HISTONE MODIFICATIONS AND WHOSE MEMBERS ALL REGULATE NF-KB. THEREFORE, THE TUMOR SUPPRESSOR MECHANISM IN 13Q14.3 UNDERLINES THE ROLE BOTH OF EPIGENETIC ABERRATIONS AND OF LNCRNA GENES IN HUMAN TUMORIGENESIS AND IS AN EXAMPLE OF COLOCALIZATION OF A FUNCTIONALLY RELATED GENE CLUSTER. 2013 17 6105 22 THE EMERGING ROLE OF LNCRNA FENDRR IN MULTIPLE CANCERS: A REVIEW. LONG NONCODING RNAS (LNCRNAS) ARE PROMINENT AS CRUCIAL REGULATORS OF TUMOR ESTABLISHMENT AND ARE REPEATEDLY DYSREGULATED IN MULTIPLE CANCERS. THEREFORE, LNCRNAS HAVE BEEN IDENTIFIED TO PLAY AN ESSENTIAL FUNCTION IN CARCINOGENESIS AND PROGRESSION OF CANCER AT GENETIC AND EPIGENETIC LEVELS. FENDRR (FETAL-LETHAL NONCODING DEVELOPMENTAL REGULATORY RNA) AS A LNCRNA IS A HALLMARK OF VARIOUS MALIGNANCIES. FENDRR IS CRUCIAL FOR MULTIPLE ORGANS' DEVELOPMENT, SUCH AS THE LUNG AND HEART. THE EFFECTS OF FENDRR UNDER SIGNALING PATHWAYS IN DIFFERENT CANCERS HAVE BEEN IDENTIFIED. IN ADDITION, IT HAS BEEN VERIFIED THAT FENDRR CAN AFFECT THE DEVELOPMENT AND PROGRESSION OF VARIOUS CANCERS. IN ADDITION, FENDRR EXPRESSION HAS BEEN ASSOCIATED WITH EPIGENETIC REGULATION OF TARGET GENES PARTICIPATING IN TUMOR IMMUNITY. FURTHERMORE, FENDRR DOWNREGULATION WAS OBSERVED IN VARIOUS TYPES OF CANCERS, INCLUDING COLORECTAL CANCER, GASTRIC CANCER, PANCREATIC CANCER, CHOLANGIOCARCINOMA, LIVER CANCER, GALLBLADDER CANCER, LUNG CANCER, BREAST CANCER, ENDOMETRIAL CANCER, PROSTATE CANCER, CHRONIC MYELOID LEUKEMIA, OSTEOSARCOMA, AND CUTANEOUS MALIGNANT MELANOMA CELLS. HERE, WE REVIEW THE BIOLOGICAL FUNCTIONS AND MOLECULAR MECHANISMS OF FENDRR IN SEVERAL CANCERS, AND WE WILL DISCUSS ITS POTENTIAL AS A CANCER BIOMARKER AND AS A PROBABLE OPTION FOR CANCER TREATMENT. 2023 18 3943 29 LNCRNA ENST00000563492 PROMOTING THE OSTEOGENESIS-ANGIOGENESIS COUPLING PROCESS IN BONE MESENCHYMAL STEM CELLS (BMSCS) BY FUNCTIONS AS A CERNA FOR MIR-205-5P. PAIN, PHYSICAL DYSFUNCTION, AND MENTAL DISORDERS CAUSED BY BONE NONUNION BRING GREAT BURDEN TO PATIENTS. BONE MESENCHYMAL STEM CELLS (BMSCS) ISOLATED FROM BONE NONUNION PATIENTS WITH POOR PROLIFERATION AND OSTEOGENIC ABILITY ARE COMPARED WITH THAT FROM NORMAL BONE-HEALING PATIENTS. LONG NONCODING RNAS (LNCRNAS) ARE A CLASS OF RNAS THAT ARE MORE THAN 200 NUCLEOTIDES IN LENGTH, LACK AN OPEN-READING FRAME ENCODING A PROTEIN, AND HAVE LITTLE OR NO PROTEIN-CODING FUNCTION, AND COULD REGULATE GENE EXPRESSION, WHICH IS INVOLVED IN THE REGULATION OF IMPORTANT LIFE ACTIVITIES, SUCH AS GROWTH, DEVELOPMENT, AGING, AND DEATH AT EPIGENETIC, TRANSCRIPTIONAL, AND POST-TRANSCRIPTIONAL LEVELS. IN THIS STUDY, WE INTENDED TO INVESTIGATE THE DIFFERENCE OF LNCRNA EXPRESSION BETWEEN PATIENTS WITH NONUNION AND NORMAL FRACTURE HEALING. OUR RESULT FOUND THAT LNCRNA ENST00000563492 WAS DOWNREGULATED IN BONE NONUNION TISSUES. LNCRNA ENST00000563492 PROMOTES OSTEOGENIC DIFFERENTIATION OF BMSCS THROUGH UPREGULATING THE EXPRESSION OF CDH11. ON THE OTHER HAND, LNCRNA ENST0000563492 COULD IMPROVE THE OSTEOGENESIS-ANGIOGENESIS COUPLING PROCESS THROUGH ENHANCING THE EXPRESSION OF VEGF DURING OSTEOGENIC DIFFERENTIATION OF BMSCS. LNCRNA ENST00000563492 FUNCTIONS AS A CERNA FOR MIR-205-5P THAT WAS TARGETING CDH11 AND VEGF. LNCRNA ENST00000563492 COULD PROMOTE THE OSTEOGENESIS OF BMSCS IN VIVO. OUR RESULT INDICATED THAT LNCRNA ENST00000563492 MAY BE A NEW TARGET FOR BONE NONUNION. 2020 19 2426 35 EPIGENETIC SILENCING OF LONG NON-CODING RNA BM742401 IN MULTIPLE MYELOMA: IMPACT ON PROGNOSIS AND MYELOMA DISSEMINATION. BACKGROUND: LONG NON-CODING RNA (LNCRNA) BM742401 IS A TUMOR SUPPRESSOR IN GASTRIC CANCER AND CHRONIC LYMPHOCYTIC LEUKEMIA. AS THE PROMOTER AND CODING REGION OF BM742401 ARE FULLY EMBEDDED IN A CPG ISLAND, WE HYPOTHESIZED THAT BM742401 IS A TUMOR SUPPRESSOR LNCRNA EPIGENETICALLY SILENCED BY PROMOTER DNA METHYLATION IN MULTIPLE MYELOMA. METHODS: METHYLATION-SPECIFIC PCR AND QUANTITATIVE BISULFITE PYROSEQUENCING WERE PERFORMED TO DETECT THE METHYLATION OF BM742401 IN NORMAL PLASMA CELLS, MYELOMA CELL LINES AND PRIMARY MYELOMA SAMPLES. THE EXPRESSION OF BM742401 WAS MEASURED BY QRT-PCR. THE FUNCTION OF BM742401 IN MULTIPLE MYELOMA CELLS WAS ANALYZED BY LENTIVIRUS TRANSDUCTION FOLLOWED BY MIGRATION ASSAY. RESULTS: BM742401 METHYLATION WAS DETECTED IN 10 (66.7%) MYELOMA CELL LINES BUT NOT NORMAL PLASMA CELLS, AND INVERSELY CORRELATED WITH EXPRESSION OF BM742401. IN PRIMARY SAMPLES, BM742401 METHYLATION WAS DETECTED IN 3 (12.5%) MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE, 9 (15.8%) MYELOMA AT DIAGNOSIS AND 8 (17.0%) MYELOMA AT RELAPSE/PROGRESSION. MOREOVER, BM742401 METHYLATION AT DIAGNOSIS WAS ASSOCIATED WITH INFERIOR OVERALL SURVIVAL (MEDIAN OS: 25 VS. 39 MONTHS; P = 0.0496). IN MYELOMA CELL LINE JJN-3, STABLE OVEREXPRESSION OF BM742401 BY LENTIVIRUS TRANSDUCTION RESULTED IN REDUCED CELL MIGRATION (P = 0.0001) BUT NOT IMPACTING CELL DEATH OR PROLIFERATION. CONCLUSIONS: THIS IS THE FIRST REPORT OF TUMOR-SPECIFIC METHYLATION-MEDIATED SILENCING OF BM742401 IN MYELOMA, WHICH IS LIKELY AN EARLY EVENT IN MYELOMAGENESIS WITH ADVERSE IMPACT ON OVERALL SURVIVAL. MOREOVER, BM742401 IS A TUMOR SUPPRESSOR LNCRNA BY INHIBITING MYELOMA CELL MIGRATION, HENCE IMPLICATED IN MYELOMA PLASMA CELL HOMING, METASTASIS AND DISEASE PROGRESSION. 2020 20 1129 30 COMPREHENSIVE ANALYSIS OF MRNA-LNCRNA CO-EXPRESSION PROFILES IN MOUSE BRAIN DURING INFECTION WITH TOXOPLASMA GONDII. TOXOPLASMA GONDII IS AN OBLIGATE INTRACELLULAR PROTOZOAN PARASITE WHICH SERIOUSLY THREATENS THE HEALTH OF DOMESTIC ANIMALS AND HUMANS. LONG NON-CODING RNAS (LNCRNAS) ARE NON-PROTEIN-CODING TRANSCRIPTS GREATER THAN 200 NUCLEOTIDES, WHICH ARE WIDELY INVOLVED IN TRANSCRIPTIONAL AND EPIGENETIC REGULATIONS. HOWEVER, LITTLE IS KNOWN ABOUT THE ROLES OF HOST LNCRNAS IN THE RESPONSE TO T. GONDII INFECTIONS. IN THIS STUDY, USING ILLUMINA SEQUENCING TECHNOLOGY, WE ANALYZED THE EXPRESSION PROFILES OF MRNAS AND LNCRNAS IN BALB/C MOUSE BRAIN FOLLOWING INFECTION BY T. GONDII PRU STRAIN (TYPE II GENOTYPE) CYSTS. THE IDENTIFIED DIFFERENTIALLY EXPRESSED (DE) RNAS WERE SUBJECTED TO BIOINFORMATICS ANALYSIS. A TOTAL OF 2,090 ANNOTATED LNCRNAS ALONG WITH 3,577 NOVEL LNCRNAS WERE IDENTIFIED. IN THE ACUTELY INFECTED MOUSE BRAIN, A TOTAL OF 330 MRNAS AND 19 LNCRNAS WERE DYS-REGULATED, WHEREAS 136 DE MRNAS AND 9 DE LNCRNAS WERE IDENTIFIED IN CHRONICALLY INFECTED MOUSE BRAIN. GO ANALYSIS REVEALED THAT THESE DE MRNAS IDENTIFIED AT ACUTE INFECTION STAGE WERE INVOLVED IN IMMUNE RESPONSE, WHEREAS DE MRNAS FOUND AT CHRONIC INFECTION STAGE WERE MOSTLY ENRICHED IN RESPONSE TO PROTOZOAN. KEGG ANALYSIS SHOWED THAT DE MRNAS WERE SIGNIFICANTLY ENRICHED IN DISEASE RELATED PATHWAYS. IN ADDITION, THE PUTATIVE MRNA-LNCRNA CO-EXPRESSION NETWORK WAS CONSTRUCTED, AND SEVERAL HUB REGULATORY RNAS WERE IDENTIFIED BASED ON THE TRANSCRIPTOME DATA. THIS STUDY FIRSTLY CHARACTERIZED THE CO-EXPRESSION PROFILE OF MRNAS AND LNCRNAS IN MOUSE BRAIN INFECTED WITH T. GONDII AND PROVIDED A FRAMEWORK FOR FURTHER STUDIES OF THE ROLES OF LNCRNAS IN HOST NEUROPATHOLOGY DURING TOXOPLASMOSIS PROGRESSION. 2023